California’s governor wants the state to establish its own generics brand in a bid to bring down the cost of prescription drugs.
A judge has refused to temporarily block California’s ban on pay-for-delay deals while a group of generics manufacturers appeal against the judge’s earlier decision.
Senju Pharmaceutical and Bausch Health have reached an “amicable settlement” to its patent suit against Aurobindo over generic Prolensa eye drops, court filings confirm.
In a partial victory for Amgen, the US Court of Appeals for the Federal Circuit concluded that a proposed generic version of Amgen’s drug Sensipar would infringe a patent earlier this week.
Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.
A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.
A group of generics manufacturers yesterday, December 2 asked the US Court of Appeals for the Ninth Circuit to reverse California’s ban on pay-for-delay deals.
California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.
Eli Lilly has won a victory in a cancer drug dispute after a federal judge ruled that Canadian pharmaceutical company Apotex’s new drug application infringed the company’s patent.
Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.